Fumio Tsuji

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6071557/publications.pdf

Version: 2024-02-01

623188 525886 37 744 14 27 citations g-index h-index papers 38 38 38 1096 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	IL-6–gp130–STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. International Immunology, 2007, 19, 695-702.	1.8	223
2	Preventive Effect of TRPV1 Agonists Capsaicin and Resiniferatoxin on Ischemia/Reperfusion-induced Renal Injury in Rats. Journal of Cardiovascular Pharmacology, 2008, 51, 513-520.	0.8	52
3	Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents. European Journal of Pharmacology, 2010, 627, 332-339.	1.7	46
4	Role of Transient Receptor Potential Vanilloid 1 in Inflammation and Autoimmune Diseases. Pharmaceuticals, 2012 , 5 , 837 - 852 .	1.7	45
5	DIFFERENTIAL EFFECTS BETWEEN MARIMASTAT, A TNF-α CONVERTING ENZYME INHIBITOR, AND ANTI-TNF-α ANTIBODY ON MURINE MODELS FOR SEPSIS AND ARTHRITIS. Cytokine, 2002, 17, 294-300.	1.4	31
6	SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF- $\hat{l}\pm$ production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo. European Journal of Pharmacology, 2008, 588, 309-315.	1.7	29
7	Involvement of Leukotriene B4 in Murine Dermatitis Models. Biochemical Pharmacology, 1998, 55, 297-304.	2.0	25
8	Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells. Immunology Letters, 1999, 68, 275-279.	1.1	25
9	Effects of SA13353, a Transient Receptor Potential Vanilloid 1 Agonist, on Leukocyte Infiltration in Lipopolysaccharide-Induced Acute Lung Injury and Ovalbumin-Induced Allergic Airway Inflammation. Journal of Pharmacological Sciences, 2010, 112, 487-490.	1.1	24
10	Involvement of leukotriene B4 in arthritis models. Life Sciences, 1998, 64, PL51-PL56.	2.0	23
11	Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. European Journal of Pharmacology, 1998, 346, 81-85.	1.7	19
12	The Effects of Betamethasone Derivatives on Endotoxin-induced Uveitis in Rats. Experimental Eye Research, 1997, 64, 31-36.	1.2	17
13	Bucillamine mechanism inhibiting IL- $\hat{1^2}$ -induced VEGF production from fibroblast-like synoviocytes. International Immunopharmacology, 2007, 7, 1569-1576.	1.7	17
14	Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice. BMC Musculoskeletal Disorders, 2009, 10, 23.	0.8	15
15	Role of Leukotriene B4 in 5-Lipoxygenase Metabolite- and Allergy-Induced Itch-Associated Responses in Mice. Biological and Pharmaceutical Bulletin, 2010, 33, 1050-1053.	0.6	14
16	Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 442-446.	1.0	11
17	IL-6-PAD4 axis in the earliest phase of arthritis in knock-in gp130F759 mice, a model for rheumatoid arthritis. RMD Open, 2019, 5, e000853.	1.8	11
18	Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model. Modern Rheumatology, 2010, 20, 381-388.	0.9	10

#	Article	IF	CITATIONS
19	The kappa opioid receptor agonist SA14867 has antinociceptive and weak sedative effects in models of acute and chronic pain. European Journal of Pharmacology, 2011, 671, 53-60.	1.7	10
20	The investigation of synovial genomic targets of bucillamine with microarray technique. Inflammation Research, 2009, 58, 571-584.	1.6	8
21	SA14867, a newly synthesized kappa-opioid receptor agonist with antinociceptive and antipruritic effects. European Journal of Pharmacology, 2010, 647, 62-67.	1.7	8
22	The role of platelet-activating factor in cell infiltration in endotoxin-induced uveitis in guinea pigs. Current Eye Research, 1998, 17, 501-505.	0.7	7
23	Effects of Sulfhydryl Compounds on Interleukin-1-Induced Vascular Endothelial Growth Factor Production in Human Synovial Stromal Cells Biological and Pharmaceutical Bulletin, 2000, 23, 663-665.	0.6	7
24	Synthesis and pharmacological evaluation of 1,1,3-substituted urea derivatives as potent TNF- \hat{l}_{\pm} production inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4479-4482.	1.0	7
25	Synthesis and biological evaluation of N-mercaptoacylproline and N-mercaptoacylthiazolidine-4-carboxylic acid derivatives as leukotriene A4 hydrolase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4529-4532.	1.0	6
26	Limited Azithromycin Localization to Rabbit Meibomian Glands Revealed by LC-MS-Based Bioanalysis and DESI Imaging. Biological and Pharmaceutical Bulletin, 2017, 40, 1586-1589.	0.6	6
27	Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model. Modern Rheumatology, 2010, 20, 381-388.	0.9	6
28	Differential effects of Akt pathway inhibitors on IL- $1\hat{l}^2$ -induced protein phosphorylation in human fibroblast-like synoviocytes. Journal of Receptor and Signal Transduction Research, 2012, 32, 22-28.	1.3	5
29	Tachykinins as enhancers of prostaglandin E2-induced intraocular inflammation. Ocular Immunology and Inflammation, 1998, 6, 19-25.	1.0	4
30	Combination effect of Bucillamine and Methotrexate on rat type II collagen-induced arthritis model. Inflammation and Regeneration, 2007, 27, 516-521.	1.5	2
31	Combination therapy with fumagillin and vaccination with tumor-derived antigenic peptides in B16 melanoma-transplanted mice. International Journal of Immunopharmacology, 1998, 20, 111-124.	1.1	1
32	Bucillamine inhibits CD40-mediated Akt activation and antibody production in mouse Bâ€eell lymphoma. International Immunopharmacology, 2012, 14, 47-53.	1.7	1
33	Transient Receptor Potential Vanilloid 1 Agonists as Candidates for Anti-inflammatory Agents. Inflammation and Regeneration, 2011, 31, 95-101.	1.5	1
34	Biomarker Identification of Tear Fluid. Metabolomics: Open Access, 2012, 2, .	0.1	1
35	The Role of STAT3 Activation in Glomerulonephritis. , 2011, , .		0
36	Biomarker Identification of Vitreous Fluid for Diabetic Retinopathy. Metabolomics: Open Access, 2012, 02, .	0.1	0

#	Article	IF	CITATIONS
37	Preventive Effect of SA13353, a Novel Transient Receptor Potential Vanilloid 1 Agonist, on Ischemia/Reperfusion-Induced Renal Injury in Rats. Advances in Pharmacology and Pharmacy, 2015, 3, 30-42.	0.1	O